search
Back to results

Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery

Primary Purpose

Premature Birth, Bacterial Vaginosis

Status
Withdrawn
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Lactobacilli GR-1 and RC-14
Sponsored by
Mount Sinai Hospital, Canada
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Premature Birth

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: pregnant women with previous incidence of preterm labour otherwise healthy over 18 years of age able to provide informed consent less than or equal to 16 weeks gestation singleton pregnancy normal uterine cavity Exclusion Criteria: significant medical complications (preeclampsia, thrombophilia, hypertension) multiple pregnancy less than 18 years of age patients receiving antibiotics or other antimicrobial therapies at time of recruitment fetal complications such as intrauterine growth restriction or other abnormalities diabetes documented need for cervical cerclage patient enrolled in other clinical trials

Sites / Locations

  • Mount Sinai Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Lactobacillus

Placebo capsules

Arm Description

Outcomes

Primary Outcome Measures

Determination if restoration of a normal vaginal flora through the use of probiotics reduces the incidence of PTB.

Secondary Outcome Measures

Full Information

First Posted
September 14, 2005
Last Updated
August 29, 2017
Sponsor
Mount Sinai Hospital, Canada
Collaborators
Canadian Institutes of Health Research (CIHR)
search

1. Study Identification

Unique Protocol Identification Number
NCT00217308
Brief Title
Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery
Official Title
Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Tightly defined inclusion criteria were making recruitment very slow.
Study Start Date
February 2005 (Actual)
Primary Completion Date
July 2007 (Anticipated)
Study Completion Date
September 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mount Sinai Hospital, Canada
Collaborators
Canadian Institutes of Health Research (CIHR)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Purpose of the study is to determine the effect of probiotic lactobacilli on the vaginal flora and cytokine profile during pregnancy, and the incidence of preterm labour in women at high risk for preterm birth.
Detailed Description
Preterm labour involves multiple causes - one of the most significant factors being a prior history of preterm birth. Infection is another major cause of preterm labour (PTL) and is estimated to cause up to 30% of PTL. Bacterial Vaginosis (BV) is an alteration in the endogenous vaginal microflora preceded by a decreased presence of Lactobacilli species and increased growth of gardnerella and other pathogens. BV is a strong risk factor for PTL, and is associated with a 40% increased risk in some populations. Initial studies suggested that the treatment of BV with antibiotics could decrease the incidence of PTL, but this has not been confirmed by randomized trials. There is substantial evidence that the "normal" lactobacillus dominated urogenital microflora play an important role in maintenance of a healthy urinary and reproductive tract. One hundred and sixty (160) women at high risk for PTL, based on a prior history of preterm birth, will be approached at their first antenatal visit to participate. Recruitment of 54 patients with symptomatic or asymptomatic BV (based on Nugent Scoring). Women with documented BV will be randomized to either treatment with lactobacilli preparation (n=27) or placebo (n=27). Women with symptomatic BV will be treated with oral Metronidazole prior to starting the lactobacilli or placebo. None of the subjects, researchers or clinical staff will know which preparation each woman receives. This study will be the first to examine the ability of lactobacilli preparations to maintain a normal vaginal flora in pregnant women. In addition, the results will potentially serve as the basis for a multi-centre RCT to determine efficacy of this treatment in preventing preterm birth.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Birth, Bacterial Vaginosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lactobacillus
Arm Type
Experimental
Arm Title
Placebo capsules
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Lactobacilli GR-1 and RC-14
Intervention Description
Probiotic Lactobacilli will be compared to placebo
Primary Outcome Measure Information:
Title
Determination if restoration of a normal vaginal flora through the use of probiotics reduces the incidence of PTB.
Time Frame
12 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: pregnant women with previous incidence of preterm labour otherwise healthy over 18 years of age able to provide informed consent less than or equal to 16 weeks gestation singleton pregnancy normal uterine cavity Exclusion Criteria: significant medical complications (preeclampsia, thrombophilia, hypertension) multiple pregnancy less than 18 years of age patients receiving antibiotics or other antimicrobial therapies at time of recruitment fetal complications such as intrauterine growth restriction or other abnormalities diabetes documented need for cervical cerclage patient enrolled in other clinical trials
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alan Bocking, MD, FRCSC
Organizational Affiliation
Chief, Department of Obstetrics and Gynaecology, Mount Sinai Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X5
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery

We'll reach out to this number within 24 hrs